U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542717) titled 'ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer' on April 08.
Brief Summary: This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.
Study Start Date: April 10
Study Type: INTERVENTIONAL
Condition:
Recurrent or Metastatic Cervical Cancer
Intervention:
DRUG: Treatment
MRG003 [Becotatug vedotin, an epidermal growth factor receptor (EGFR)-tar...